Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Natalizumab (Primary) ; Methylprednisolone; Prednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 16 Sep 2015 Planned End Date changed from 1 Apr 2019 to 1 Aug 2019 as reported by ClinicalTrials.gov record.